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Summary:
We investigate the feasibility of CD34-selected peripheral
blood stem cell (PBSC) transplantation followed by pre-
emptive CD8-depleted donor lymphocyte infusions (DLI)
after a minimal conditioning regimen. Six patients with
advanced hematological malignancies ineligible for a
conventional myeloablative transplant (n¼ 5) or meta-
static renal cell carcinoma (n¼ 1), and with an HLA-
identical (n¼ 4) or alternative (n¼ 2) donor were
included. The nonmyeloablative conditioning regimen
consisted in 2Gy TBI alone (n¼ 4), 2Gy TBI and
ﬂudarabine (RCC patient, n¼ 1) or cyclophosphamide
and ﬂudarabine (patient who had previously received
12Gy TBI, n¼ 1). Post transplant immunosuppression
was carried out with cyclosporin (CyA) and mycopheno-
late mofetil (MMF). Initial engraftment was achieved in
all patients. One out of six patients (17%) experienced
grade X2 acute GVHD only after abrupt cyclosporin
discontinuation and a interferon therapy for life-threaten-
ing tumor progression. T-cell chimerism was 23% (19–30)
on day 28, 32% (10–35) on day 100, 78% (49–95) on day
180 and 99.5% (99–100) on day 365. Three out of four
patients who had measurable disease before the transplant
experienced a complete response. We conclude that
CD34-selected NMSCT followed by CD8-depleted DLI
is feasible and preserves engraftment and apparently also
the graft-versus-leukemia (GVL) effect. Further studies
are needed to conﬁrm this encouraging preliminary report.
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In an attempt to reduce mortality associated with
allogeneic myeloablative hematopoietic stem cell transplan-
tation (HSCT) in elderly patients or in patients relapsing
after a previous transplant, nonmyeloablative conditioning
regimens have been developed with the aim of obtaining
donor engraftment and using the graft-versus-leukemia
(GVL) effect to eradicate underlying malignancies.1–3 After
extensive preclinical studies, 4–8 the Seattle team developed
a nonmyeloablative HSCT approach combining 2Gy
TBIþ 90mg/m2 ﬂudarabine as the conditioning regimen
and postgrafting immunosuppression with cyclosporin
(CyA) and mycophenolate mofetil (MMF).5 This approach
was recently shown to be feasible (even in patients who
were ineligible for a conventional transplant) with a low
transplant-related mortality (TRM) that was most often
attributed to graft-versus-host disease (GVHD) and/or
infections.9,10 Thus, reduction in the incidence of GVHD is
a major challenge to improve the outcome of NMSCT
recipients.
In animal models, two conditions are required to obtain
powerful GVL effects without GVHD after allogeneic
HSCT. The ﬁrst condition is the absence of GVH-reactive
T cells in the initial donor graft, and the second is to allow
sufﬁcient time for the recipient to recover from condition-
ing-induced inﬂammation before administering donor
lymphocyte infusions (DLI).11,12 In humans, several reports
have demonstrated the feasibility of such an approach in
the myeloablative transplant setting.13 The aim of this pilot
study was to examine the feasibility of CD34-selected
NMSCT followed by preemptive CD8-depleted DLI.
Study design
Patients
Six consecutive male patients aged 35–65 (median 61) years
and ineligible for a myeloablative allogeneic transplant
were included. Their clinical characteristics are summarized
in Table 1. Written informed consent was obtained from
patients and donors and our institution’s Ethical Commit-
tee approved the protocol.Received 28 March 2003; accepted 6 May 2003
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Conditioning and transplant procedure
Donors (HLA-identical siblings (n¼ 4) or one-mismatch
related donor (n¼ 2)) received human G-CSF at 10 mg/kg
from day 5 to day 1 before transplant. Collection of
peripheral blood stem cell (PBSC) was carried out on days
1 and 0, using a continuous ﬂow blood cell separator
(CS3000þ , Baxter-Fenwall Laboratories, Deerﬁeld, IL,
USA or Cobe Spectra, Lakewood, CO, USA). Immediately
after the second harvest, PBSC from the ﬁrst and second
harvests were pooled and CD34þ cell selection was carried
out using the Isolex 300i& magnetic cell separator (Baxter),
according to the manufacturers’ recommendations as
previously reported.14,15 Nonmyeloablative conditioning
regimens consisted of 2Gy TBI alone (n¼ 4), 2Gy TBI
and 30mg/m2/day ﬂudarabine for 3 days (RCC patient) or
cyclophosphamide (1 g/m2/day for 3 days) and ﬂudarabine
(an NHL patient who had previously received 12Gy TBI).
Post transplant immunosuppression was carried out with
CyA (CyA, from day –1 to day 180 or longer in case of
alternative donor or chronic GVHD) and mycophenolate
mofetil (MMF, 15mg/kg b.i.d. from day 1 to day 28) as
previously described.14
Donor lymphocyte infusions
Around day 40 post transplantation, donors underwent 12–
16 l leukaphereses on two consecutive days to collect
lymphocytes. CD8-depletion was carried out with Baxter
Isolex 300i& as previously reported.14 Patients received
CD8-depleted DLI at doses of 1 107 and 5 (2 in
mismatched transplants) 107 CD3þ cells/kg recipient
around days 40 and 80, respectively. We chose that
schedule of pre-emptive CD8-depleted DLI because we
had previously shown that it was safe after a myeloablative
CD34-selected HSCT.14,16 Patients with mixed chimerism
on day 100 or with progressive disease received additional
DLI (Table 1). The ﬁrst DLI was infused fresh while the
following ones were cryopreserved and thawed.
Clinical management
The diagnosis and grading of acute and chronic GVHD
was established as previously reported.17,18 Disease evalua-
tion was routinely carried out on days 40, 100, 180 and 365.
Laboratory analyses
Aliquots of the pooled PBSC as well as the CD34-selected
fractions were incubated with phycoerythrin (PE)-conju-
gated anti-CD34, CD3, CD4, CD8 and CD56 monoclonal
antibodies for 20min at 201C, washed and ﬁxed. A total of
1 105 cells/condition was analyzed using an FACS-scan
analyzer (Becton-Dickinson). The percentage of CD34þ
cells was deﬁned with dot plot analysis using the whole
nucleated cell population. The percentage of positive cells
in the isotype control was subtracted from the CD34þ
percentage to give the ﬁnal percentage of CD34þ cells.
Data acquisition was performed with the Cellquest soft-
ware (Becton-Dickinson).
Chimerism among peripheral blood T cells and myeloid
cells as well as in unfractionated marrow was assessed on
days 28, 42, 60, 80, 100, 120, 180, 240, 365 and 730 after
HCT. For recipients of sex-mismatched transplants (n¼ 2),
chimerism was assessed by ﬂuorescence in situ hybridiza-
tion (FISH) to detect X and Y chromosomes. For
recipients of sex-matched transplants (n¼ 4), chimerism
was assessed by a PCR assay with multiplex ampliﬁcation
of nine STR-loci and ﬂuorescence detection as described by
Thiede et al.19 CD3 (T cells) and CD13/CD33 (myeloid
cells) selection was carried out with an FACStar Plus sorter
(Becton-Dickinson) or with RosetteSep (StemCell
technologies, Vancouver, Canada). Mixed chimerism
(MC) was deﬁned as between 5 and 94% donor cells and
full chimerism (FC) as X95% donor cells.
Statistical analyses
The probability of GVHD, TRM and survival were studied
by life-table analyses. Statistical analyses were carried out




None of the six patients developed grade 2 or higher
regimen-related toxicities.20 Donor cells engrafted in all
patients. The neutrophil nadir occurred on day 7 and was
1.3 (0.12–1.32) 109/l. Three out of six patients received a
median of four (0–7) doses of G-CSF for treatment of
neutropenia. The median platelet nadir was 67 (10–
165) 109/l and only 1/6 patients (17%) required one
platelet transfusion. Finally, the median Hb nadir was 9.8
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Figure 1 Evolution of T (a) and myeloid (b) cell chimerism.
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(9.2–13.5) g/dl and one patient required RBC transfusion
during the ﬁrst month after HSCT because of angina
pectoris.
Chimerism
The evolution of chimerism is shown in Figure 1. Median T
cell (CD3þ ) and myeloid cell (CD13þ or CD33þ )
chimerisms were 23% (19–30) and 85% (70–100), respec-
tively, on day 28; 32% (10–35) and 94% (90–100),
respectively on day 100; 78% (49–95) and 98% (90–100),
respectively on day 180 and 99.5% (99–100) and 99.5%
(99–100), respectively on day 365. CD3 and CD13
chimerisms 2 years after the transplant were 100 and
100%, respectively, in patient 1 and 100 and 100%,
respectively, in patient 2.
GVHD
Only one out of six patients (17%) experienced grade X2
acute GVHD. This patient had been transplanted for
Table 1 Patients, donors and clinical evolution
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Patient
Age/sex 65/M 43/M 65/M 65/M 35/M 58/M
Underlying disease CLL NHL RCC MM HD NHL









Number of previous regimens 3 4a 1 3 4 3
Donor
Age/sex 61/F 40/M 44/M 58/F 32/M 24/M
Relationship Sibling Sibling Child Sibling Sibling Child
HLA compatibility HLAid HLAid 1MM HLAid HLAid 1MM
Graft
CD34+/kg infused ( 106) 1.83 5.71 7.28 2.19 8.79 5.36
CD3+/kg infused ( 106) 0.08 0.11 0.08 0.05 0.04 0.05
DLI : CD3+/kg infused ( 106)
DLI 1 (day 40) 10 10 10 10 10 10
DLI 2 (day 80) 50 50 20 50 50 20
DLI 3 [dose (day)] 50 (120) — — 50 (230) 50 (230) 25 (110)
DLI 4 [dose (day)] 20c (220) — — — — —
DLI 5 [dose (day)] 50c (280) — — — — —
DLI 6 [dose (day)] 50c (360) — — — — —
Graft-versus-host disease
Acute GVHD (grade) 1 0 3d 0 0 0
Chronic GVHD Limited Extensive N/A No Limited Extensive
Disease evolution
Best response achieved CR CR PD CR CR CR
Current disease status CR CR Death CR CR CR
Survival
Survival status (day) Alive (844+) Alive (838+) Death (119) Alive (378+) Alive (376+) Alive (336+)
Cause of death — — Progression — — —
aAlso previous auto-HSCT for HD.
bCR1 was achieved only after radiotherapy and CR2 only after auto-transplantation.
cUnmanipulated.
dAfter abrupt CyA discontinuation and a-Interferon therapy for life-threatening tumor progression.
RD¼ refractory disease; CR¼ complete remission; CLL¼ chronic lymphoid leukemia; NHL¼ non-Hodgkin’s lymphoma; RCC¼ renal cell carcinoma,
MM¼multiple myeloma, HD¼Hodgkin’s disease, N/A¼ not applicable.












Figure 2 Disease evolution in patient 1. Leukemic cells (broken line)
disappeared progressively after DLI (black arrows), as donor cells
increased in the bone marrow.
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metastatic RCC and developed grade 3 acute GVHD after
abrupt CyA discontinuation and a-interferon therapy
for life-threatening tumor progression. Four patients
developed limited (n¼ 2) or extensive (n¼ 2) chronic
GVHD.
Response
Three out of four patients who had measurable disease
before the transplant achieved CR (Figure 2 and Table 1).
The third one, transplanted for refractory metastatic RCC,
died of progressive disease 120 days after the transplant
(Table 1). The two patients transplanted for poor-risk
lymphoma in CR remained in CR (Table 1).
Discussion
Two previous preliminary reports have studied the
feasibility of NMSCT with CD34-selected PBSC after a
nonmyeloablative conditioning regimen combining 2Gy
TBI and ﬂudarabine21,22 (Table 2). Four out of ﬁve patients
reported by Kreiter et al rejected their transplant 37–210
days after NMSCT. Major differences with our protocol
include: (1) no pre-emptive DLI before day 100; and (2)
discontinuation of CyA and MMF between days 15 and 50
in patients without GVHD. DLI given early (around day
40) after a T-cell depleted NMSCT have been previously
reported to convert mixed into complete donor
chimerism.23,24 Thus, we hypothesized that CD8-depleted
pre-emptive DLI given in our patients on days 40 and 80
after the transplant were critical to avoid transplant
rejection. Similarly, it has been shown that extending the
duration of CyA from 35 to 100 days after the transplant
favorably inﬂuenced stable donor engraftment in dogs
conditioned with 100 cGy TBI and post grafting immuno-
suppression combining CyA and MMF. Thus, extending
the duration of CyA administration in our patients possibly
also had a favorable impact.
Gorner et al 22 reported the evolution of six patients
transplanted with CD34-selected PBSC after a conditioning
regimen combining 2Gy TBI and ﬂudarabine even in
previously heavily treated patients. Post grafting immuno-
suppression was carried out with CyA (extended until day
100 after the transplant) and MMF (Table 2). The authors
reported the achievement of stable mixed chimerism in 5/6
Table 2 Previous studies of CD34-selected NMSCT using the Seattle’s conditioning regimen
Kreiter et al21 Gorner et al22 Baron et al
Diagnosis
Multiple myeloma 3 5 1
Lymphoma 0 0 3
Chronic lymphocytic leukemia 1 0 1
Acute myeloid leukemia 0 1 0
Renal cell carcinoma 0 0 1
Chediak–Higashi syndrome 1 0 0
Previous regimens
Standard-dose chemotherapy: yes/no 4/1 6/0 5/1
Autologous transplantation: yes/no 3/2 5/1 4/2
Conditioning regimen
2Gy TBI alone 4 0 3
2Gy TBI+ﬂudarabine 1 6 2
Cyclophosphamide+ﬂudarabine 0 0 1
Immunosuppression
CyA+MMF: yes/no 5/0 6/0 6/0
Day of CyA discontinuation, median (in patients without GVHD) 50 100 195 (per protocol)
Donor type
Matched related 3 2 4
Mismatched related 1 2 2
Matched unrelated 1 2 0
Cells given on day 0 ( 106/Kg)
CD34+ 4.6 (3–8) 8.3 (5.5–11.1) 5.5 (1.8–8.8)
CD3+ 2 (0.1–2) 0.1 (0.1–0.3) 0.06 (0.04–0.1)
Donor lymphocyte infusion
Yes/No 2/3 3/3 6/0
Median day of ﬁrst DLI 115 80 40
CD3+cells given in ﬁrst DLI ( 106/kg), median 0.1 1 10a
Graft rejection: yes (days)/no 4 (37, 125, 150, 210)/1 1 (100)/5 0/6
Acute GVHD X2: yes/no 1/4 1/5 1/5
aCD8-depleted.
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patients treated. Unfortunately, the follow-up of their
patients was quite short and the authors did not report the
evolution of T cell chimerism. Our study shows that full
donor chimerism is achievable after conditioning with 2Gy
TBI only.
We elected to deplete pre-emptive DLI of CD8þ cells
because previous studies have shown that CD8-depletion of
DLI decreased the risk of GVHD without impairing the
GVL effect nor the ability of DLI to convert mixed
chimerism into full donor chimerism.25–27
Owing to the low number of patients included in this
pilot study, no conclusion can be drawn on the incidence of
GVHD or occurrence of the GVL effect. However, the
incidence of acute GVHD was low in our study compared
to that previously reported in unmanipulated NMSCT
recipients.9,28 Moreover, a GVL effect was observed in
three out of four patients who had measurable disease
before the transplant.
The evolution of T-cell chimerism in our patients is quite
interesting. In unmanipulated NMSCT recipients, low
T-cell chimerism on day 28 after the transplant is strongly
correlated with graft rejection.9,29 However, despite of low
T-cell chimerism on day 28 (median 23%) in our patients,
we did not observe any graft rejection. As mentioned
above, we believe that pre-emptive CD8-depleted DLI as
well as extension of CyA administration in our patients
were critical to avoid transplant rejection. However, it
should be noted that no patient in our study was at high
risk of transplant rejection (such as CML or MDS patients)
and, at our center, we limit this transplantation approach
to patients at low/intermediate risk of transplant rejection.
Childs et al 30 have previously reported that GVL effects
occurred mostly after achievement of full donor chimerism.
As the time to achieve full donor T-cell chimerism seems to
be markedly delayed in our patients, we believe that this
NMSCT approach must be restricted to patients at high
risk of GVHD and with a slowly progressing disease.
In conclusion, CD34-selected NMSCT followed by CD8-
depleted DLI is feasible, preserves engraftment and
apparently also the GVL effect. Further studies are needed
to conﬁrm this encouraging preliminary report.
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